Business Wire

Dame Maggie Smith and Other Harry Potter Film Actors Join Jam City’s Harry Potter: Hogwarts Mystery

Share

Jam City:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180405005187/en/

Dame Maggie Smith as Professor McGonagall, in Harry Potter: Hogwarts Mystery from Jam City (Photo: B ...

Dame Maggie Smith as Professor McGonagall, in Harry Potter: Hogwarts Mystery from Jam City (Photo: Business Wire)

Who: Jam City, a Los Angeles based mobile games studio, in partnership with Warner Bros. Interactive Entertainment.

What:

  • Actors from the Harry Potter films will provide voiceover work for Jam City’s Harry Potter: Hogwarts Mystery. A full list of actors providing voice work for the game include:
    • Dame Maggie Smith (Professor McGonagall)
    • Michael Gambon (Professor Dumbledore)
    • Warwick Davis (Professor Flitwick)
    • Sally Mortemore (Madam Irma Pince)
    • Gemma Jones (Madam Pomfrey)
    • Zoe Wanamaker (Madam Hooch)
  • Global launch date for Harry Potter: Hogwarts Mystery confirmed to be Wednesday, April 25th on iOS and Android.

Where: Los Angeles, California

Quotes:
“If I could attend Hogwarts as a student, I would be most excited to attend the potions class taught by Severus because it is the most exotic,” said Dame Maggie Smith, voice of Professor McGonagall.

"Our goal with Harry Potter: Hogwarts Mystery is to make players really feel for the first time like they’re attending Hogwarts,” said Chris DeWolfe, co-founder and CEO of Jam City. “By including these iconic and incredibly talented actors in the game, we come one step closer to truly giving fans their own Hogwarts experience.”

Assets: To download supporting assets for Harry Potter: Hogwarts Mystery , please visit: https://app.box.com/v/HPHogwartsMystery-TalentReveal

Background: Harry Potter: Hogwarts Mystery is the first mobile game where players can create their own character and experience life as a Hogwarts student. In the narrative adventure with RPG elements, players will create a personalized student avatar, attend classes, learn magical skills, and form friendships or rivalries with other students. In the game, players make pivotal decisions that influence their character’s story arc at Hogwarts. The game features a new encounter system where player decisions and actions impact their quests, allowing Harry Potter fans to create their own legacy as a witch or wizard.

For more details on Harry Potter: Hogwarts Mystery and to connect with other fans, visit www.facebook.com/HPHogwartsMystery/, www.twitter.com/HogwartsMystery, and for more information visit www.HarryPotterHogwartsMystery.com/.

About Jam City:
Jam City is a global leader in mobile entertainment, providing social gaming experiences for millions of players around the world. Jam City was founded in 2010 by MySpace cofounders Chris DeWolfe and Aber Whitcomb, and former 20th Century Fox executive Josh Yguado. Jam City is the creative powerhouse behind some of the highest grossing and most enduring social gaming franchises for mobile, including Cookie Jam (Facebook “Game of the Year” winner) and Panda Pop. Jam City is the go-to studio for Hollywood, having developed immersive, narrative rich mobile games around iconic entertainment brands including Harry Potter, Family Guy, and Marvel Avengers. Jam City has 500 employees across studios in Los Angeles (HQ), San Francisco, San Diego, Seattle and Buenos Aires. The Jam City team is known for its creative excellence and technological innovation in key areas including storytelling, data science and consumer insights.

About Warner Bros. Interactive Entertainment:
Warner Bros. Interactive Entertainment, a division of Warner Bros. Home Entertainment, Inc., is a premier worldwide publisher, developer, licensor and distributor of entertainment content for the interactive space across all platforms, including console, handheld, mobile and PC-based gaming for both internal and third party game titles.

About Portkey Games:
Portkey Games, from Warner Bros. Interactive Entertainment, is a games label dedicated to creating Wizarding World™ gaming experiences inspired by the vision of J.K. Rowling. These new games allow players to explore, discover and be at the centre of their very own Wizarding World™ adventure.

About the Harry Potter Series:
Harry Potter continues to be a global phenomenon. Each of the seven books by author J.K. Rowling has broken sales records, with the series to date having sold over 500 million copies worldwide and translated into 80 languages. The Harry Potter films, produced by Warner Bros. Pictures, have grossed more than $7.7 billion to date worldwide at the box office, making Harry Potter one of the largest-grossing film franchises in history.

HARRY POTTER: HOGWARTS MYSTERY software © 2018 Jam City, Inc. Developed by Jam City. Jam City® and the Jam City Logo are registered and/or unregistered trademarks of Jam City, Inc. WIZARDING WORLD, HARRY POTTER and FANTASTIC BEASTS Publishing Rights © J.K. Rowling. PORTKEY GAMES, HARRY POTTER: HOGWARTS MYSTERY, WIZARDING WORLD, HARRY POTTER and FANTASTIC BEASTS characters, names and related indicia © and ™ Warner Bros. Entertainment Inc. All Rights Reserved

WB GAMES LOGO, WB SHIELD: ™ & © Warner Bros. Entertainment Inc. (s18)

Editor’s Note:
To download supporting assets for Harry Potter: Hogwarts Mystery , please visit: https://app.box.com/v/HPHogwartsMystery-TalentReveal

Contact information

Jam City
Sarah Ross, 310-924-1404
sarahr@jamcity.com
or
Kenny Johnston, 602-999-1890
kjohnston@jamcity.com
or
ONE PR Studio (for Jam City in the US)
Kjell Vistad | Gilberto Williams-Gamboa
510-893-3271
jamcity@oneprstudio.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Source Photonics Announces a Comprehensive Portfolio of 50Gb/s Optical Transceivers for 5G Mid-Haul Applications23.9.2019 02:48:00 EESTPress release

Source Photonics, a market leader of optical transceivers for wireless applications, announces a comprehensive portfolio of 50Gb/s products serving 5G mid-haul applications. Source Photonics’ product portfolio leverages 30 years of high-speed optical transceiver development and high-volume shipments into wireless, datacenter and routing applications, resulting in a broad portfolio of optical transceivers supporting data rates ranging from 125Mb/s to 400Gb/s and transmitting between 300m and 40 km. Source Photonics has leveraged early investments in signal integrity, firmware development, and uncooled high speed DML packaging to release the industry’s most broad 50G product portfolio. 50Gb/s, selected as the mid-haul data rate, provides mid-haul bandwidth requirements not supported by 25Gb/s while also offering meaningful economic advantages over traditional 100Gb/s transceivers. Furthermore, 50Gb/s data rate products support bi-directional applications, where fiber availability is scar

Celltrion Healthcare Receives CHMP Positive Opinion for Novel Subcutaneous Formulation of CT-P13 (biosimilar infliximab) for the Treatment of People With Rheumatoid Arthritis23.9.2019 02:01:00 EESTPress release

Celltrion Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for CT-P13 SC for marketing authorisation in the European Union (EU) in people with rheumatoid arthritis (RA). CT-P13 SC is the subcutaneous version of Remsima® (biosimilar infliximab, CT-P13). This recommendation will now be reviewed by the European Commission, which has the authority to approve medicines in the EU. A subcutaneous formulation has the potential to enhance treatment options for the use of biosimilar infliximab by providing high consistency in drug exposure and a convenient method of administration.1,2 “Today’s positive CHMP opinion brings us one step closer to providing a personalised treatment approach for people living with rheumatoid arthritis. This marks an important milestone for our business providing people with a new route of administration, and a novel formulation of infliximab,” said Hyoung-Ki

Source Photonics Demonstrates a Full 400G Product Portfolio at ECOC 201923.9.2019 02:01:00 EESTPress release

Source Photonics, a leading vendor of optical connectivity products for Access and Datacom applications, will demonstrate its complete 400G portfolio with industry partners at ECOC 2019 from September 23-25. Source Photonics has added a wide range of new products to its industry leading portfolio of single-mode products for datacenter and routing applications. The new products leverage the company’s multi-year investment in 28Gbaud and 53Gbaud PAM4 technology and support 400G applications for reaches from 500m up to 40km in small form factor transceivers. Source Photonics’ portfolio of Datacenter and Routing products includes: 400G-DR4 supporting 400GE links over 500m as well as an enhanced reach of up to 2 km (4x100G-FR) with support for breakout into 100G-DR/FR 400G-LR8 supporting 400GE links up to 10 km 400G-ER8 supporting 400GE links up to 40km as technology demonstration “Successful interoperability between optical transceivers and hosts is crucial to rolling out the next higher d

 Ipsen to Present New Data at 13th Annual Conference of the International Liver Cancer Association (ILCA 2019)20.9.2019 19:30:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today presents results from the matching-adjusted indirect comparison (MAIC) of cabozantinib (Cabometyx®) versus regorafenib (Stivarga®) for the second-line treatment (2L) of patients with advanced hepatocellular carcinoma (aHCC) who received sorafenib as the only prior systemic therapy. Using data from the Phase III CELESTIAL and RESORCE trials, the MAIC showed that cabozantinib offers greater efficacy versus regorafenib. Using data from the Phase III CELESTIAL and RESORCE trials, the MAIC showed that in the 2L CELESTIAL sub-population who had received sorafenib as the only prior systemic therapy, cabozantinib significantly improved progression-free survival (PFS), with an additional 2.4 months provided vs. regorafenib (5.6 months vs. 3.2 months [95% confidence interval (CI): 4.90-7.26], p<0.05). Median overall survival (OS) was also favorable with cabozantinib (11.4 months vs. 10.8 months), though statistical significance was not met

RoboSense RS-LiDAR-M1 Smart LiDAR Sensor Wins AutoSens Awards 201920.9.2019 16:30:00 EESTPress release

On September 18, 2019, RoboSense announced at Brussels, Belgium that its flagship product RS-LiDAR-M1 Smart LiDAR Sensor has been awarded the elite AutoSens Awards trophy in the “Best Automotive Safety System” category, given to only the highest-rated innovative product or technology in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190920005309/en/ Robosense Along With Other Winnners At The Autosens Awards Ceremony At Brussels, Belgium (Photo: Business Wire) True autonomous driving requires human-like advanced sensing of the environment for driving with little or no human input. The safety of passengers and passers-by is always the priority concern for autonomous driving. When the RS-LiDAR-M1 is integrated into the current autonomous driving car perception system, it overcomes the weaknesses of millimeter wave radar and camera technologies on identifying obstacles, and eliminates car accidents, such

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases20.9.2019 15:00:00 EESTPress release

Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases. By combining Inflammasome’s unique intravitreal (IVT) drug delivery technologies with Boehringer Ingelheim’s compounds from its retinal disease pipeline portfolio, Boehringer Ingelheim aims to develop novel therapies for retinal diseases. In 2019 there were an estimated 82 million patients in the seven key countries (U.S., Japan, Germany, U.K., Spain, Italy, France) affected by one of the three major forms of retinal disease: Age related macular degeneration (AMD), diabetic retinopathy (DR), and diabetic macular edema (DME). Globally, the prevalence rates of these and other retinal diseases are expected to increase over the next 10 years primarily due to aging populations and the global diabetes epidemic. Despite therapeutic advances in some disease areas during the past

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom